Robert Gut Sells 25,613 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 25,613 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Robert Gut also recently made the following trade(s):

• On Thursday, November 6th, Robert Gut sold 31,434 shares of uniQure stock. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84.

uniQure Stock Performance

Shares of uniQure stock traded up $0.85 on Wednesday, reaching $22.35. 1,443,119 shares of the stock were exchanged, compared to its average volume of 2,039,311. The business has a 50 day moving average price of $25.06 and a two-hundred day moving average price of $27.73. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -5.09 and a beta of 0.68. uniQure N.V. has a twelve month low of $7.76 and a twelve month high of $71.50. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. Analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QURE has been the topic of several research analyst reports. The Goldman Sachs Group dropped their price objective on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. Stifel Nicolaus dropped their price target on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Royal Bank Of Canada decreased their price target on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research note on Monday, November 3rd. Mizuho cut their price target on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, December 8th. Finally, UBS Group set a $95.00 price target on uniQure in a report on Thursday, September 25th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.82.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA purchased a new stake in uniQure during the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp grew its position in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the third quarter worth $50,000. FNY Investment Advisers LLC raised its holdings in uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.